Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Shares Outstanding (2016 - 2025)

Spyre Therapeutics (SYRE) has disclosed Shares Outstanding for 10 consecutive years, with $51.4 million as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Shares Outstanding rose 1169.35% year-over-year to $51.4 million, compared with a TTM value of $51.4 million through Sep 2024, up 1169.35%, and an annual FY2023 reading of $36.1 million, up 1279.38% over the prior year.
  • Shares Outstanding was $51.4 million for Q3 2024 at Spyre Therapeutics, up from $50.8 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $65.4 million in Q1 2023 and bottomed at $2.0 million in Q4 2021.
  • Average Shares Outstanding over 5 years is $33.2 million, with a median of $44.6 million recorded in 2020.
  • The sharpest move saw Shares Outstanding plummeted 95.97% in 2022, then soared 1467.38% in 2024.
  • Year by year, Shares Outstanding stood at $48.0 million in 2020, then crashed by 95.88% to $2.0 million in 2021, then skyrocketed by 32.42% to $2.6 million in 2022, then skyrocketed by 1279.38% to $36.1 million in 2023, then skyrocketed by 42.54% to $51.4 million in 2024.
  • Business Quant data shows Shares Outstanding for SYRE at $51.4 million in Q3 2024, $50.8 million in Q2 2024, and $36.6 million in Q1 2024.